Alle Fotos(1)

Dokumente

PHR1055

Famotidin

Name: Famotidin
Brand: SIAL

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(e):

N′-(Aminosulfonyl)-3-{[2-(diaminomethylenamino)-4-thiazolyl]-methylthio}-propanamidin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):

C₈H₁₅N₇O₂S₃

CAS-Nummer:

76824-35-6

Molekulargewicht:

337.45

MDL-Nummer:

MFCD00079297

UNSPSC-Code:

41116107

PubChem Substanz-ID:

329823085

NACRES:

NA.24

Empfohlene Produkte

Slide 1 of 9

1 of 9

USP

1269200

Famotidin

Supelco

PHR2909

Famotidin-verwandte Verbindung B

Supelco

PHR2910

Famotidin-verwandte Verbindung C

Supelco

PHR2911

Famotidin-verwandte Verbindung D

USP

1269243

Famotidin-verwandte Verbindung D

BP653

Famotidin

F0005000

Famotidin

Y0000382

Famotidin für die Systemeignung

Supelco

PHR1275

Naphthalin

Biologische Quelle

synthetic

Qualitätsniveau

300

Qualität

certified reference material
pharmaceutical secondary standard

Agentur

BP
EP
USP
traceable to BP 653
traceable to Ph. Eur. F0050000
traceable to USP 1269200

Dampfdruck

<0.0000001 kPa ( 25 °C)

API-Familie

famotidine

Analysenzertifikat (CofA)

current certificate can be downloaded

Verpackung

pkg of 1 g

Lagerbedingungen

protect from light (20 mm aluminium crimp seal for unused portion)

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

Farbe

white to pale yellow-white

mp (Schmelzpunkt)

325.4-327.2 °F (163—164°C)

Löslichkeit

DMF: freely soluble
acetone: practically insoluble
chloroform: practically insoluble
ethanol: practically insoluble
ether: practically insoluble
ethyl acetate: practically insoluble
glacial acetic acid: freely soluble
methanol: slightly soluble
water: very slightly soluble

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Versandbedingung

ambient

Lagertemp.

2-8°C

SMILES String

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

InChIKey

XUFQPHANEAPEMJ-UHFFFAOYSA-N

Angaben zum Gen

human ... HRH2(3274)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Famotidine is a histamine H2-receptor antagonist, which promotes the healing of erosive esophagitis, gastric and duodenal ulcers since it inhibits the gastric acid secretion in humans.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Anwendung

Famotidine may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using different chromatography techniques.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem./physiol. Wirkung

H₂ Histamin-Rezeptorantagonist; Antiulcusmittel

Hinweis zur Analyse

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Sonstige Hinweise

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Fußnote

To see an example of a Certificate of Analysis for this material enter LRAA7133 in the slot below. This is an example certificate only and may not be the lot that you receive.

1269243

1269265

1269221

1269232

1269254

BP653

Famotidin, British Pharmacopoeia (BP) Reference Standard

PHR2908

PHR2909

PHR2910

Famotidin-verwandte Verbindung C

PHR2911

Famotidin-verwandte Verbindung D

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 9

1 of 9

USP

1598405

Ranitidin -hydrochlorid

Supelco

PHR1645

Sodium Iron EDTA

Supelco

PHR1600

Topiramat

Supelco

PHR1059

Omeprazol

Supelco

PHR1056

Trimethoprim

Supelco

PHR1683

Celecoxib

Sigma-Aldrich

R101

Ranitidin -hydrochlorid

Supelco

PHR1057

Furosemid

Supelco

PHR1026

Ranitidin -hydrochlorid

The

Profiles of Drug Substances, Excipients, and Related Methodology (2011)

GC Determination of famotidine, ranitidine, cimetidine, and metformin in pharmaceutical preparations and serum using methylglyoxal as derivatizing reagent

Majidano AS, et al.

Chromatographia, 75(21-22), 1311-1317 (2012)

High-performance thin-layer chromatography for the determination of ranitidine hydrochloride and famotidine in pharmaceuticals.

Novakovic J.

Journal of Chromatography A, 846(1-2), 193-198 (1999)

Famotidine suppresses osteogenic differentiation of tendon cells in vitro and pathological calcification of tendon in vivo.

Kenichi Yamamoto et al.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 30(12), 1958-1962 (2012-05-18)

Heterotopic ossification or calcification follows any type of musculoskeletal trauma and is known to occur after arthroplasties of hip, knee, shoulder, or elbow; fractures; joint dislocations; or tendon ruptures. Histamine receptor H2 (Hrh2) has been shown to be effective for

Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer.

Abolfazl Razzaghdoust et al.

The Prostate, 74(1), 41-47 (2013-09-11)

Ionizing radiation causes a series of hematological alterations especially profound lymphocytopenia during and after the radiotherapy course. To investigate whether famotidine can reduce hematologic toxicity in patients treated with radiotherapy for prostate cancer. A total of 36 patients undergoing radiotherapy

Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.

Dokumente

Famotidin

Pharmaceutical Secondary Standard; Certified Reference Material

About This Item

Empfohlene Produkte

Eigenschaften

Biologische Quelle

Qualitätsniveau

Qualität

Agentur

Dampfdruck

API-Familie

Analysenzertifikat (CofA)

Verpackung

Lagerbedingungen

Methode(n)

Farbe

mp (Schmelzpunkt)

Löslichkeit

Anwendung(en)

Format

Versandbedingung

Lagertemp.

SMILES String

InChI

InChIKey

Angaben zum Gen

Verwandte Kategorien

Beschreibung

Allgemeine Beschreibung

Anwendung

Biochem./physiol. Wirkung

Hinweis zur Analyse

Sonstige Hinweise

Fußnote

Verwandte Produkte

Ähnliches Produkt

Sicherheitshinweise

Lagerklassenschlüssel

WGK

Flammpunkt (°F)

Flammpunkt (°C)

Dokumentation

Analysenzertifikate (COA)

Besitzen Sie dieses Produkt bereits?

Kunden haben sich ebenfalls angesehen

Peer-Reviewed-Artikel

Technischer Dienst